HK1210599A1 - 防止濫用的控釋藥物組合物 - Google Patents

防止濫用的控釋藥物組合物

Info

Publication number
HK1210599A1
HK1210599A1 HK15111389.9A HK15111389A HK1210599A1 HK 1210599 A1 HK1210599 A1 HK 1210599A1 HK 15111389 A HK15111389 A HK 15111389A HK 1210599 A1 HK1210599 A1 HK 1210599A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
controlled release
abuse deterrent
deterrent pharmaceutical
abuse
Prior art date
Application number
HK15111389.9A
Other languages
English (en)
Inventor
Peter Holm Tygesen
Karsten Lindhart
Martin Rex Olsen
Gina Engslev Fischer
Jan Martin Vergrd
Georg Boye
Nikolaj Skak
Torben Elhauge
Original Assignee
Egalet Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48703579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1210599(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Egalet Ltd filed Critical Egalet Ltd
Publication of HK1210599A1 publication Critical patent/HK1210599A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15111389.9A 2012-07-06 2015-11-18 防止濫用的控釋藥物組合物 HK1210599A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261668741P 2012-07-06 2012-07-06
DKPA201270405 2012-07-06
PCT/EP2013/063851 WO2014006004A1 (en) 2012-07-06 2013-07-01 Abuse deterrent pharmaceutical compositions for controlled release

Publications (1)

Publication Number Publication Date
HK1210599A1 true HK1210599A1 (zh) 2016-04-29

Family

ID=48703579

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111389.9A HK1210599A1 (zh) 2012-07-06 2015-11-18 防止濫用的控釋藥物組合物

Country Status (13)

Country Link
US (3) US9549899B2 (zh)
EP (1) EP2877161A1 (zh)
JP (1) JP2015521988A (zh)
KR (1) KR20150059167A (zh)
CN (1) CN104684548A (zh)
AU (1) AU2013285988A1 (zh)
BR (1) BR112015000150A2 (zh)
CA (1) CA2877183A1 (zh)
EA (1) EA201590165A1 (zh)
HK (1) HK1210599A1 (zh)
MX (1) MX2014015880A (zh)
NZ (1) NZ704011A (zh)
WO (1) WO2014006004A1 (zh)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
CN104684548A (zh) 2012-07-06 2015-06-03 埃格勒特有限责任公司 防止滥用的控释药物组合物
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3082775A4 (en) * 2013-12-17 2017-05-17 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
PL3164117T3 (pl) 2014-07-03 2024-03-11 SpecGx LLC Preparaty zapewniające natychmiastowe uwalnianie i powstrzymujące przed nadużywaniem, zawierające polisacharydy inne niż celuloza
DK3169315T3 (da) * 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
ES2886901T3 (es) 2015-03-13 2021-12-21 Jackson Lab Un sistema complejo CRISPR/Cas de tres componentes y usos del mismo
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
WO2017087373A1 (en) * 2015-11-16 2017-05-26 Actavis Elizabeth Llc Modified release abuse deterrent tablet
MX2018008868A (es) * 2016-02-08 2018-09-21 SpecGx LLC Composiciones farmaceuticas que contienen glucomanano con liberacion extendida y propiedades disuasivas de abuso.
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
DK3562486T3 (da) 2016-12-31 2024-06-10 Bioxcel Therapeutics Inc Anvendelse af sublingual dexmedetomidin til behandling af agitation
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3473246A1 (en) 2017-10-19 2019-04-24 Capsugel Belgium NV Immediate release abuse deterrent formulations
WO2019126125A1 (en) * 2017-12-20 2019-06-27 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
US10624856B2 (en) 2018-01-31 2020-04-21 Dharma Laboratories LLC Non-extractable oral solid dosage forms
CA3103440A1 (en) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
JP7488201B2 (ja) 2018-06-27 2024-05-21 バイオエクセル セラピューティクス，インコーポレイテッド デクスメデトミジンを含むフィルム製剤、及びその作製方法
CA3112030A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020070547A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
AU2019352028A1 (en) 2018-10-05 2021-03-11 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US20210378989A1 (en) 2018-10-11 2021-12-09 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
US20210322321A1 (en) * 2018-10-19 2021-10-21 Temple University-Of The Commonwealth System Of Higher Education Tamper-resistant drug dosage forms and methods of making and use thereof
JP2022540706A (ja) 2019-07-19 2022-09-16 バイオエクセル セラピューティクス，インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
US20230063459A1 (en) 2019-12-30 2023-03-02 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
WO2021137148A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
KR102461699B1 (ko) * 2021-05-21 2022-11-03 현대약품 주식회사 벤지다민염산염을 포함하는 안정성이 개선된 가글액
WO2023168022A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocybin
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (269)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2685553A (en) 1951-03-30 1954-08-03 Winthrop Stearns Inc Cement coated tablets
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB1430684A (en) 1972-06-26 1976-03-31 Lowey H Prolonged release lozenges
JPS5518694B2 (zh) 1973-04-02 1980-05-21
US4034758A (en) 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4330338A (en) 1978-10-02 1982-05-18 Purdue Research Foundation Pharmaceutical coating composition, and preparation and dosages so coated
US4449983A (en) 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
DE3320583A1 (de) 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
AU591171B2 (en) 1983-11-02 1989-11-30 Alza Corporation Dispenser for delivering thermo-responsive composition
US4844984A (en) 1984-03-19 1989-07-04 Alza Corporation Dispensing system with means for increasing delivery of beneficial agent from the system
JPH0246008B2 (ja) 1984-06-01 1990-10-12 Takada Seiyaku Kk Nifuejipinjizokuseiseizainoseizohoho
GB2170104A (en) 1985-01-30 1986-07-30 Warner Lambert Co Coated pharmaceutical dosage forms
IE59066B1 (en) 1985-02-19 1993-12-15 Key Pharma Controlled release potassium chloride
US4898733A (en) 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US4892742A (en) 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
US4824675A (en) 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
AU3432689A (en) 1988-03-24 1989-10-16 Bukh Meditec A/S Controlled release composition
FI101344B1 (fi) 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
JPH07100191B2 (ja) 1989-01-04 1995-11-01 古河電気工業株式会社 ブランキング方法
EP0455648B1 (en) 1989-01-30 1993-03-10 Alza Corporation Dosage form for administering calcium antagonist
US5019396A (en) 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
EP0435726B1 (en) 1989-12-29 1994-11-09 Bristol-Myers Squibb Company Capsule and caplet combination
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
GB9025372D0 (en) 1990-11-22 1991-01-09 Nat Res Dev Pharmaceutical dosage forms
GB9101502D0 (en) 1991-01-23 1991-03-06 Controlled Therapeutics Sct Controlled release compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
SE9202250D0 (sv) 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
US5869097A (en) 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
US5881926A (en) 1993-03-11 1999-03-16 Taro Pharmaceutical Industries, Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
US5656291A (en) 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
SE9301057L (sv) 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US6183778B1 (en) 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
JPH07100191A (ja) 1993-10-06 1995-04-18 Daikyo Yakuhin Kogyo Kk 徐放性坐剤
US5419917A (en) 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
EP0746310B1 (en) 1994-02-23 1998-11-18 BM Research A/S Controlled release composition
US7060293B1 (en) 1994-05-25 2006-06-13 Purdue Pharma Powder-layered oral dosage forms
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US6491945B1 (en) 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
IL139728A (en) 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
DE69709646T2 (de) 1996-03-12 2002-08-14 Alza Corp., Palo Alto Zusammensetzung und dosisform mit einem opioid-antagonisten
ES2319699T3 (es) 1996-05-20 2009-05-11 Otsuka Pharmaceutical Co., Ltd. Remedio para la rosacea.
US6348216B1 (en) 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
US6361794B1 (en) 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
JP2000516222A (ja) 1996-08-15 2000-12-05 ロザン ファルマ ゲゼルシャフトミットベシュレンクテル ハフツング 嚥下が容易な経口医薬組成物
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
JP2000514101A (ja) 1997-07-01 2000-10-24 ファイザー・インク セルトラリン塩及びセルトラリンの持続性剤形
US6730326B2 (en) 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US20020054911A1 (en) 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
FR2774910B1 (fr) 1998-02-16 2001-09-07 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de fabrication et preparations pharmaceutiques
US8524277B2 (en) 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
DK1067910T3 (da) 1998-04-03 2004-10-04 Egalet As Komposition med styret afgivelse
US7906143B1 (en) 1998-10-05 2011-03-15 Intellipharmaceutics Corp Controlled release pharmaceutical delivery device and process for preparation thereof
US20080113025A1 (en) 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20080102121A1 (en) 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
ATE433318T1 (de) 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
IL138990A0 (en) 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
FR2794646B1 (fr) 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
US6225343B1 (en) 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
US6534085B1 (en) 1999-09-23 2003-03-18 Bioresponse L.L.C. Phytochemicals for promoting weight loss
ES2374717T3 (es) 1999-10-29 2012-02-21 Euro-Celtique S.A. Formulaciones de hidrocodona de liberación controlada.
WO2001035958A1 (en) 1999-11-15 2001-05-25 Smithkline Beecham Corporation Carvedilol methanesulfonate
US6458824B1 (en) 1999-11-30 2002-10-01 Dainippon Pharmaceutical Co., Ltd. Solid preparation
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6491949B2 (en) 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US20010053791A1 (en) 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
US20010036959A1 (en) 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
WO2001074356A1 (en) 2000-04-03 2001-10-11 F. Hoffmann-La Roche Ag Concentrated solutions of carvedilol
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
JP2004518734A (ja) 2000-10-24 2004-06-24 スミスクライン・ビーチャム・コーポレイション カルベジロールの新規処方
WO2002036099A1 (en) 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
DE60110192T2 (de) 2000-12-07 2006-03-09 Warner-Lambert Company Llc Verfahren und System zur gleichmäßigen Arzneistoffabgabe
US6800668B1 (en) 2001-01-19 2004-10-05 Intellipharmaceutics Corp. Syntactic deformable foam compositions and methods for making
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
IN191028B (zh) 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
MXPA04001206A (es) * 2001-08-06 2004-07-08 Euro Celtique Sa Composiciones y metodos para prevenir el abuso de opioides.
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
EP1929998A3 (en) 2001-09-21 2008-11-26 Egalet A/S Controlled release solid dispersions of carvedilol
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
WO2003026625A1 (en) 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Modified release dosage forms
US20060039958A1 (en) 2003-05-28 2006-02-23 Monosolrx, Llc. Multi-layer films having uniform content
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
EP1471891A4 (en) 2002-02-08 2007-04-11 Alkermes Inc POLYMER-BASED COMPOSITIONS FOR PROLONGED RELEASE
ITMI20020514A1 (it) 2002-03-12 2003-09-12 Jagotec Ag Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi
PT1485078E (pt) 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran para o tratamento do síndrome do intestino irritável
WO2003082204A2 (en) 2002-03-26 2003-10-09 Euro-Celtique S.A. Sustained-release gel coated compositions
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
AU2003234216A1 (en) 2002-04-29 2003-11-17 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
DE10223844B4 (de) 2002-05-28 2013-04-04 Danfoss A/S Wasserhydraulische Maschine
RU2004134728A (ru) 2002-05-31 2005-06-10 Алза Корпорейшн (Us) Дозированные формы и композиции для осмотической доставки различных дозировок оксикодона
AR039744A1 (es) 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
US20040089605A1 (en) 2002-11-08 2004-05-13 Harry Brandt Reverse osmosis liquid purification system and method
AU2003275953A1 (en) 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
US20040102476A1 (en) 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
WO2004054542A2 (en) 2002-12-13 2004-07-01 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
EP1572164A2 (en) 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
DK1610768T3 (da) 2003-03-26 2008-09-22 Egalet As Matrikskompositioner til styret afgivelse af lægemiddelsubstanser
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MXPA05011071A (es) 2003-04-21 2005-12-12 Euro Celtique Sa Forma de dosificacion resistente a la alteracion que comprende particulas co-extrusionadas de agente adverso y proceso de fabricacion de las misma.
PL1631251T3 (pl) 2003-04-24 2011-12-30 Jagotec Ag Tabletka o opóźnionym uwalnianiu i o określonej geometrii
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20060177507A1 (en) 2003-05-22 2006-08-10 Joaquina Faour Controlled release device containing lercanidipine
CN1812773B (zh) 2003-05-28 2012-06-27 莫诺索尔克斯有限公司 基于聚氧乙烯的薄膜及由其制造的药物传递系统
US20060165790A1 (en) 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
CA2533165A1 (en) 2003-07-21 2005-01-27 Bio-Dar Ltd. Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
NZ545202A (en) 2003-08-06 2010-03-26 Gruenenthal Chemie Abuse-proofed dosage form comprising opiods and a high molecular weight polyethylene oxide
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004020220A1 (de) 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20050053655A1 (en) 2003-09-05 2005-03-10 Pharmaceutical Industry Technology And Development Center Rapid disintegrating tablets (RDTs) for pharmaceutical use and method for preparing the same
KR100782918B1 (ko) 2003-09-19 2007-12-07 펜웨스트 파머슈티칼즈 컴파니 지연 방출성 제형
CA2540056C (en) 2003-09-26 2015-03-24 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
WO2005034859A2 (en) 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US8883204B2 (en) 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
DE502004005072D1 (de) 2003-12-17 2007-11-08 Ksb Ag Drucktauschersystem
CA2550866A1 (en) 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
WO2005065654A2 (en) 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone formulations
WO2005102286A1 (de) 2004-04-22 2005-11-03 Grünenthal GmbH Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreinchungsform
ES2517244T3 (es) 2004-05-11 2014-11-03 Egalet Ltd. Forma farmacéutica hinchable que comprende goma gellan
WO2005123039A1 (en) 2004-06-12 2005-12-29 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
DE102004032103A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
WO2006002883A1 (de) 2004-07-01 2006-01-12 Grünenthal GmbH Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreichungsform unter verwendung eines planetwalzenextruders
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
PL1765303T5 (pl) 2004-07-01 2023-05-22 Grünenthal GmbH Tabletka doustna zabezpieczona przed nadużywaniem
PL1786403T3 (pl) 2004-07-01 2013-10-31 Gruenenthal Gmbh Doustna postać dawki zabezpieczona przed nadużywaniem zawierająca (1R, 2R)-3-(3-dimetyloamino-1-etylo0-2-metylo-propylo)fenol
DE102004038440A1 (de) 2004-08-07 2006-03-16 Ksb Aktiengesellschaft Drehzahlregelbarer Druckaustauscher
US7214315B2 (en) 2004-08-20 2007-05-08 Scott Shumway Pressure exchange apparatus with integral pump
US20070281007A1 (en) 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
WO2006030402A2 (en) 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Dual compartment osmotic delivery device
US20060110327A1 (en) 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
FR2889810A1 (fr) 2005-05-24 2007-02-23 Flamel Technologies Sa Forme medicamenteuse orale, microparticulaire, anti-mesurage
FR2881652B1 (fr) 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
KR100822519B1 (ko) 2005-02-15 2008-04-16 주식회사종근당 위장 내에서 제어방출되는 단일 매트릭스 정제
US20060193912A1 (en) 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co. Controlled release O-desmethylvenlafaxine formulations
JP2008534564A (ja) 2005-03-28 2008-08-28 オレクソ・アクチエボラゲット 痛みの治療に有用な新しい製薬組成物
GB0506982D0 (en) 2005-04-06 2005-05-11 Mw Encap Ltd Abuse resistant capsules
WO2006128471A2 (en) 2005-06-03 2006-12-07 Egalet A/S A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
PE20070325A1 (es) 2005-06-29 2007-05-12 Alza Corp Formas de dosificacion oral que comprenden compuestos derivados de carbamato
US8858993B2 (en) 2005-07-25 2014-10-14 Metrics, Inc. Coated tablet with zero-order or near zero-order release kinetics
US20080166407A1 (en) 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
AU2006287342A1 (en) 2005-09-09 2007-03-15 Monosol Rx Llc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090022798A1 (en) 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20100172989A1 (en) 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
AU2007205866B2 (en) 2006-01-21 2012-11-29 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
US20070264346A1 (en) 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
FR2898056B1 (fr) 2006-03-01 2012-01-20 Ethypharm Sa Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
AU2007225101A1 (en) 2006-03-15 2007-09-20 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
KR101495146B1 (ko) 2006-03-16 2015-02-24 트리스 파마 인코포레이티드 약물 - 이온교환 수지 복합체를 함유하는 변형 방출 제제
CA2647801C (en) 2006-03-24 2015-04-14 Auxilium Pharmaceuticals, Inc. Process for the preparation of a hot-melt extruded laminate
ES2619906T3 (es) 2006-03-24 2017-06-27 Auxilium International Holdings, Llc Composiciones estabilizadas que contienen fármacos lábiles alcalinos
EP2457563B1 (en) 2006-05-09 2017-03-22 Mallinckrodt LLC Zero-order modified release solid dosage forms
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
FR2901478B1 (fr) 2006-05-24 2015-06-05 Flamel Tech Sa Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
MX2008016223A (es) 2006-06-23 2009-01-19 Elan Pharma Int Ltd Composiciones que comprenden naproxen nanoparticulado e hidrocodona de liberacion controlada.
CA2660650A1 (en) 2006-06-23 2007-12-27 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
NZ574544A (en) 2006-08-04 2011-12-22 Ethypharm Sa Granule and orally disintegrating tablet comprising oxycodone
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2008028047A2 (en) 2006-08-30 2008-03-06 Lab International Srl Bioadhesive film drug delivery system
WO2008027442A2 (en) 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8211905B1 (en) 2007-05-22 2012-07-03 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
DE102006057364B4 (de) 2006-12-04 2011-08-25 Danfoss A/S Wasserhydraulische Maschine
WO2008068471A1 (en) 2006-12-04 2008-06-12 Orexo Ab New non-abusable pharmaceutical composition comprising opioids
CA2930487A1 (en) 2007-01-16 2008-07-24 Egalet Ltd. Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8329720B1 (en) 2007-05-22 2012-12-11 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
MX336861B (es) 2007-09-13 2016-02-04 Cima Labs Inc Formulacion de farmaco resistente al abuso.
CA2959274C (en) 2007-12-06 2019-07-09 Pain Therapeutics, Inc. Micronized opioid compositions, formulations and dosage forms and methods of making same
WO2009075782A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
RU2010129907A (ru) 2007-12-17 2012-01-27 Лабофарм Инк. (CA) Лекарственная форма с контролируемым высвобождением, предотвращающая неправильное употребление
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
KR101094231B1 (ko) 2008-02-18 2011-12-14 하나제약 주식회사 서방성 고형 제제 및 그의 제조방법
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
JP5607550B2 (ja) 2008-03-11 2014-10-15 ディポメド，インコーポレイティド 非オピオイド鎮痛剤及びオピオイド鎮痛剤の組合せを含む胃保持性持続放出剤形
WO2010017821A1 (en) 2008-08-14 2010-02-18 Daniel Bar-Shalom Coated tablets with a remaining degradation surface over the time8
DE102008044869A1 (de) 2008-08-29 2010-03-04 Danfoss A/S Umkehrosmosevorrichtung
BRPI0913724B8 (pt) 2008-09-18 2021-05-25 Purdue Pharma Lp formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo
ES2414856T3 (es) 2008-12-12 2013-07-23 Paladin Labs Inc. Formulaciones de fármaco narcótico con potencial de adicción disminuido
ES2509497T3 (es) 2008-12-16 2014-10-17 Paladin Labs Inc. Formulación de liberación controlada para evitar un uso indebido
EP2389169A1 (en) * 2009-01-26 2011-11-30 Egalet A/S Controlled release formulations with continuous efficacy
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2393487B1 (en) 2009-02-06 2016-11-02 Egalet Ltd. Pharmaceutical compositions resistant to abuse
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
US9056054B2 (en) 2009-06-25 2015-06-16 Elite Laboratories, Inc. Abuse resistant oral dosage forms
BR112012001466A2 (pt) 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
NZ596667A (en) 2009-07-22 2013-09-27 Gruenenthal Chemie Hot-melt extruded controlled release dosage form
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
WO2011079074A1 (en) 2009-12-24 2011-06-30 Acura Phamaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
US20110195989A1 (en) 2010-02-09 2011-08-11 Rudnic Edward M Controlled Release Formulations of Opioids
US20120321674A1 (en) 2011-02-17 2012-12-20 Michael Vachon Technology for Preventing Abuse of Solid Dosage Forms
US20130022646A1 (en) 2010-02-09 2013-01-24 Rudnic Edward M Controlled Release Formulations of Opioids
MX347753B (es) 2010-02-24 2017-05-10 Cima Labs Inc Formulaciones resistentes al abuso.
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
ES2534847T3 (es) 2010-09-02 2015-04-29 Grünenthal GmbH Forma de dosificación inviolable que comprende un polímero aniónico
PE20131126A1 (es) 2010-09-02 2013-10-21 Gruenenthal Chemie Forma de dosificacion resistente a alteracion que comprende un polimero anionico
EP2618820A2 (en) 2010-09-24 2013-07-31 Qrxpharma Limited Controlled release formulations of opioids
WO2012061779A1 (en) 2010-11-04 2012-05-10 Abbott Gmbh & Co. Kg Drug formulations
GB201020895D0 (en) 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
EP2651399A2 (en) 2010-12-13 2013-10-23 Purdue Pharma LP Controlled release dosage forms
MY166034A (en) 2010-12-22 2018-05-21 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
US9233073B2 (en) 2010-12-23 2016-01-12 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
MX2013009492A (es) 2011-02-17 2014-07-30 Qrxpharma Ltd Tecnologia para prevenir el abuso de formas de dosificacion solidas.
RS54152B1 (en) 2011-03-25 2015-12-31 Purdue Pharma L.P. PHARMACEUTICAL DOSAGE FORMS WITH CONTROLLED RELEASE
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
MX348054B (es) 2011-07-29 2017-05-25 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco.
JP6110384B2 (ja) 2011-09-16 2017-04-05 パーデュー ファーマ エルピー 不正改変抵抗性医薬製剤
ES2703688T3 (es) 2011-09-16 2019-03-12 Purdue Pharma Lp Formulaciones de liberación inmediata resistentes a alteración
MX2014003973A (es) 2011-10-06 2014-05-07 Gruenenthal Gmbh Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide.
EP2768537B1 (en) 2011-10-18 2019-02-20 Purdue Pharma LP Acrylic polymer formulations
MX349725B (es) 2011-11-17 2017-08-10 Gruenenthal Gmbh Forma de dosificacion farmaceutica oral a prueba de manipulacion que comprende un agente antagonista y/o aversivo opioide, oxido de polialquileno y un polimero anionico.
EP2782558A4 (en) 2011-11-22 2015-03-18 Watson Pharmaceuticals Inc MISSABLE TABLET WITH IMMEDIATE RELEASE
AU2012327231B2 (en) 2011-12-09 2015-09-24 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
CN104684548A (zh) 2012-07-06 2015-06-03 埃格勒特有限责任公司 防止滥用的控释药物组合物
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile

Also Published As

Publication number Publication date
US20140220126A1 (en) 2014-08-07
EP2877161A1 (en) 2015-06-03
CN104684548A (zh) 2015-06-03
KR20150059167A (ko) 2015-05-29
NZ704011A (en) 2016-04-29
BR112015000150A2 (pt) 2017-06-27
MX2014015880A (es) 2015-08-05
WO2014006004A1 (en) 2014-01-09
AU2013285988A1 (en) 2015-02-12
CA2877183A1 (en) 2014-01-09
US9549899B2 (en) 2017-01-24
EA201590165A1 (ru) 2015-08-31
US9044402B2 (en) 2015-06-02
US20170181974A1 (en) 2017-06-29
JP2015521988A (ja) 2015-08-03
US20140010873A1 (en) 2014-01-09
US20170333354A9 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
HK1210599A1 (zh) 防止濫用的控釋藥物組合物
IL234997B (en) Immediate release pharmaceutical preparations designed to prevent abuse
IL234996A0 (en) Hand-release pharmacy preparations with properties to prevent abuse
IL236648A0 (en) Delayed release abuse prevention pharmaceuticals
HK1209638A1 (zh) 藥物組合物
ZA201501930B (en) Pharmaceutical composition
IL228441A0 (en) Controlled-release pharmaceutical dosage forms
EP2782558A4 (en) MISSABLE TABLET WITH IMMEDIATE RELEASE
ZA201202474B (en) Controlled release compositions
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
HK1208222A1 (zh) 用於蛋白酶體抑制劑的改性釋放製劑
GB201205164D0 (en) Pharmaceutical compounds
GB2502402B (en) Controlled drug release
HK1216619A1 (zh) 藥物化合物
ZA201502987B (en) Pharmaceutical composition
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
GB201211153D0 (en) Pharmaceutical compositions
GB201202027D0 (en) Pharmaceutical compounds
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
LT2874611T (lt) Skrandyje neiri uždelsto atpalaidavimo farmacinė forma
IL238075A0 (en) pharmaceutical preparations
ZA201400751B (en) Pharmaceutical composition
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions
GB201204810D0 (en) Pharmaceutical compositions